Using Ribonucleoprotein-based CRISPR/Cas9 to Edit Single Nucleotide on Human Induced Pluripotent Stem Cells to Model Type 3 Long QT Syndrome (SCN5A±)
-
Published:2023-08-31
Issue:8
Volume:19
Page:2774-2789
-
ISSN:2629-3269
-
Container-title:Stem Cell Reviews and Reports
-
language:en
-
Short-container-title:Stem Cell Rev and Rep
Author:
Ge Ning, Liu Min, Li Rui, Allen Nicholas M., Galvin Joseph, Shen Sanbing, O’Brien Timothy, Prendiville Terence W.ORCID
Abstract
AbstractHuman induced pluripotent stem cells (hiPSCs) have been widely used in cardiac disease modelling, drug discovery, and regenerative medicine as they can be differentiated into patient-specific cardiomyocytes. Long QT syndrome type 3 (LQT3) is one of the more malignant congenital long QT syndrome (LQTS) variants with an SCN5A gain-of-function effect on the gated sodium channel. Moreover, the predominant pathogenic variants in LQTS genes are single nucleotide substitutions (missense) and small insertion/deletions (INDEL). CRISPR/Cas9 genome editing has been utilised to create isogenic hiPSCs to control for an identical genetic background and to isolate the pathogenicity of a single nucleotide change. In this study, we described an optimized and rapid protocol to introduce a heterozygous LQT3-specific variant into healthy control hiPSCs using ribonucleoprotein (RNP) and single-stranded oligonucleotide (ssODN). Based on this protocol, we successfully screened hiPSCs carrying a heterozygous LQT3 pathogenic variant (SCN5A±) with high efficiency (6 out of 69) and confirmed no off-target effect, normal karyotype, high alkaline phosphatase activity, unaffected pluripotency, and in vitro embryonic body formation capacity within 2 weeks. In addition, we also provide protocols to robustly differentiate hiPSCs into cardiomyocytes and evaluate the electrophysiological characteristics using Multi-electrode Array. This protocol is also applicable to introduce and/or correct other disease-specific variants into hiPSCs for future pharmacological screening and gene therapeutic development.
Graphical Abstract
Funder
National Children's Research Centre Galway University Foundation College of Medicine, Nursing and Health Sciences, National University of Ireland, Galway China Sponsorship Council National University Ireland, Galway
Publisher
Springer Science and Business Media LLC
Reference46 articles.
1. Mizusawa, Y., Horie, M., & Wilde, A. A. (2014). Genetic and clinical advances in congenital long QT syndrome. Circulation Journal, 78(12), 2827–2833. https://doi.org/10.1253/circj.cj-14-0905 2. Ackerman, M. J., Priori, S. G., Willems, S., Berul, C., Brugada, R., Calkins, H., Camm, A. J., Ellinor, P. T., Gollob, M., Hamilton, R., Hershberger, R. E., Judge, D. P., Le Marec, H., McKenna, W. J., Schulze-Bahr, E., Semsarian, C., Towbin, J. A., Watkins, H., Wilde, A., … Zipes, D. P. (2011). HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm, 8(8), 1308–1339. https://doi.org/10.1016/j.hrthm.2011.05.020 3. Porta-Sánchez, A., Spillane, D. R., Harris, L., Xue, J., Dorsey, P., Care, M., Chauhan, V., Gollob, M. H., & Spears, D. A. (2017). T-wave morphology analysis in congenital long QT syndrome discriminates patients from healthy individuals. JACC Clin Electrophysiol., 3(4), 374–381. https://doi.org/10.1016/j.jacep.2016.10.013 4. Kim, H. J., Kim, B. G., Park, J. E., Ki, C. S., Huh, J., Youm, J. B., Kang, J. S., & Cho, H. (2019). Characterization of a novel LQT3 variant with a selective efficacy of mexiletine treatment. Science and Reports, 9(1), 12997. https://doi.org/10.1038/s41598-019-49450-0 5. Novak, A., Barad, L., Lorber, A., Gherghiceanu, M., Reiter, I., Eisen, B., Eldor, L., Itskovitz-Eldor, J., Eldar, M., Arad, M., & Binah, O. (2015). Functional abnormalities in iPSC-derived cardiomyocytes generated from CPVT1 and CPVT2 patients carrying ryanodine or calsequestrin mutations. Journal of Cellular and Molecular Medicine, 19(8), 2006–2018. https://doi.org/10.1111/jcmm.12581
|
|